Editorial Team

Bevacizumab: The Angiogenesis Inhibitor Redefining Cancer Care

Bevacizumab (Avastin) has transformed cancer treatment since its approval in 2004, offering new hope to patients with advanced cancers. This targeted therapy works by inhibiting vascular endothelial growth factor-A (VEGF-A), a key protein that fuels tumor growth by promoting new blood vessel formation. By blocking VEGF-A, bevacizumab cuts off a tumor’s blood supply, slowing its

Bevacizumab: The Angiogenesis Inhibitor Redefining Cancer Care Read More »